First Pacific Advisors Has Lifted Sm Energy Company (SM) Stake By $10.91 Million; Last Week Adamas Pharmaceuticals, Inc. (ADMS) Analysts

June 14, 2018 - By Adrian Mccoy

SM Energy Company (NYSE:SM) Logo

Among 13 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Adamas Pharmaceuticals had 36 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of ADMS in report on Wednesday, August 9 with “Buy” rating. As per Friday, June 17, the company rating was initiated by Noble Financial. The rating was initiated by Aegis Capital with “Buy” on Tuesday, September 22. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Tuesday, February 20 with “Buy” rating. Piper Jaffray maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Thursday, February 22 with “Buy” rating. On Thursday, April 28 the stock rating was maintained by Mizuho with “Neutral”. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Mizuho on Thursday, June 16. Credit Suisse maintained the shares of ADMS in report on Thursday, December 24 with “Outperform” rating. The firm has “Buy” rating by Needham given on Friday, February 23. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Thursday, April 19 with “Buy” rating. See Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) latest ratings:

19/04/2018 Broker: Mizuho Rating: Buy New Target: $49.0000 Maintain
04/04/2018 Broker: Leerink Swann Rating: Buy New Target: $31.0000 Initiate
27/03/2018 Broker: Bank of America Rating: Buy New Target: $39 Initiates Coverage On
09/03/2018 Broker: Mizuho Rating: Buy New Target: $49.0 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $49.0 Maintain
23/02/2018 Broker: Needham Rating: Buy New Target: $40.0 Maintain
20/02/2018 Broker: Evercore Rating: Buy New Target: $85.0 Maintain
20/02/2018 Broker: Mizuho Rating: Buy New Target: $48.0 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $55.0 Maintain
23/01/2018 Broker: Mizuho Rating: Buy New Target: $48.0 Maintain

First Pacific Advisors Llc increased Sm Energy Company (SM) stake by 33.84% reported in 2018Q1 SEC filing. First Pacific Advisors Llc acquired 606,013 shares as Sm Energy Company (SM)’s stock rose 20.60%. The First Pacific Advisors Llc holds 2.40M shares with $43.21M value, up from 1.79M last quarter. Sm Energy Company now has $2.73 billion valuation. The stock decreased 1.61% or $0.4 during the last trading session, reaching $24.43. About 1.80M shares traded. SM Energy Company (NYSE:SM) has risen 27.06% since June 14, 2017 and is uptrending. It has outperformed by 14.49% the S&P500. Some Historical SM News: ; 17/04/2018 – SM ENERGY SAYS 1Q TOTAL PRODUCTION EXCEEDS HIGH END OF GUIDANCE; 26/03/2018 – SM ENERGY CO – PRODUCTION ASSOCIATED WITH POWDER RIVER BASIN ASSET SALE IS REMOVED FROM NET PRODUCTION AS OF APRIL 1, 2018; 04/04/2018 – SM Energy Sales Include Remaining Assets in Williston Basin Located in Divide County, North Dakota; 03/05/2018 – SM Energy 1Q Adj EPS 7c; 26/03/2018 – SM ENERGY CO – BASED ON FIRST TWO MONTHS OF QUARTER, PERMIAN BASIN PRODUCTION EXCEEDED PLAN; 04/04/2018 – SM ENERGY CO – BUYERS ARE NOT DISCLOSED; 04/04/2018 – SM ENERGY CO -ANNOUNCES SALE OF REMAINING ASSETS IN WILLISTON BASIN AND ONE FOR SALE OF ITS THIRD-PARTY OPERATED ASSETS HALFF EAST; 15/05/2018 – Wexford Adds SM Energy, Exits Parsley Energy: 13F; 26/03/2018 – SM ENERGY CO – TOTAL CAPITAL SPEND FOR 2018 IS EXPECTED TO APPROXIMATE $1.27 BLN, WITH HIGHER EXPENDITURES IN FIRST HALF OF YEAR; 03/05/2018 – SM Energy 1Q EPS $2.81

The stock increased 0.11% or $0.03 during the last trading session, reaching $27.47. About 370,755 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since June 14, 2017 and is uptrending. It has outperformed by 76.18% the S&P500. Some Historical ADMS News: ; 25/04/2018 – USGS: M 4.3 – 58km W of Adamas, Greece; 15/03/2018 – ADAMAS PHARMACEUTICALS – ANNOUNCES RESULTS FROM TWO POOLED PHASE 3 STUDIES IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA; 15/05/2018 – Perceptive Advisors Buys New 2.3% Position in Adamas Pharma; 26/03/2018 – ADAMAS FIN ASIA LTD ADAM UP OWNERSHIP IN HKMH; 19/04/2018 – Adamas Announces Final Results From Phase 3 Study of GOCOVRI in Parkinson’s Disease Patients With Dyskinesia; 26/03/2018 – Adamas Pharma Presenting at Conference Tomorrow; 19/04/2018 – Adamas: Patients Receiving Gocovri Experienced Long-Term Durability for Up to Two Years; 15/03/2018 – ADAMAS PHARMACEUTICALS INC -; 15/05/2018 – Sectoral Asset Management Buys 1.3% Position in Adamas Pharma; 19/04/2018 – Adamas Pharma Closes Above 50-Day Moving Average: Technicals

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $741.20 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

More recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Announces New Employment Inducement Grant” on June 08, 2018. Also Seekingalpha.com published the news titled: “Adamas Pharmaceuticals: Interesting Over The Long Term” on May 18, 2018. Nasdaq.com‘s news article titled: “Adamas Announces Publication of Pharmacokinetic Data for GOCOVRIâ„¢ in Clinical Pharmacokinetics” with publication date: May 24, 2018 was also an interesting one.

Investors sentiment increased to 1.16 in Q1 2018. Its up 0.12, from 1.04 in 2017Q4. It is positive, as 25 investors sold SM shares while 66 reduced holdings. 32 funds opened positions while 74 raised stakes. 122.88 million shares or 4.51% more from 117.58 million shares in 2017Q4 were reported. Point72 Asset Mngmt Lp holds 0.12% in SM Energy Company (NYSE:SM) or 1.63 million shares. The Ohio-based Bartlett & Co Limited Com has invested 0.01% in SM Energy Company (NYSE:SM). Perkins Cap Mngmt holds 0.2% of its portfolio in SM Energy Company (NYSE:SM) for 12,175 shares. Liberty Mutual Grp Asset Management Inc has 20,226 shares for 0.01% of their portfolio. State Board Of Administration Of Florida Retirement Systems owns 167,620 shares. Assetmark holds 0% in SM Energy Company (NYSE:SM) or 43 shares. State Of Alaska Department Of Revenue, a Alaska-based fund reported 8,700 shares. Macquarie Group Ltd owns 0.11% invested in SM Energy Company (NYSE:SM) for 3.32M shares. Vanguard Incorporated has invested 0.01% of its portfolio in SM Energy Company (NYSE:SM). Envestnet Asset Management holds 0% or 152 shares in its portfolio. Rhumbline Advisers invested in 0.01% or 195,105 shares. Eaton Vance Mngmt has 0% invested in SM Energy Company (NYSE:SM). Trexquant Lp, Connecticut-based fund reported 59,105 shares. Pcj Inv Counsel Limited invested 0.03% in SM Energy Company (NYSE:SM). National Bank & Trust Of Montreal Can owns 113,574 shares or 0% of their US portfolio.

First Pacific Advisors Llc decreased Oracle Corporation (NYSE:ORCL) stake by 2.46M shares to 18.64M valued at $852.74 million in 2018Q1. It also reduced Citigroup Inc (NYSE:C) stake by 605,008 shares and now owns 6.93 million shares. Franks Intl N V (NYSE:FI) was reduced too.

Another recent and important SM Energy Company (NYSE:SM) news was published by Prnewswire.com which published an article titled: “SM Energy To Redeem Senior Notes Due 2021” on June 14, 2018.

SM Energy Company (NYSE:SM) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>